Combined Chemotherapy and Immunotherapy Shows Promise for Advanced Prostate Cancers
Researchers at the University of California, San Diego School of Medicine report that blocking or removing immune-suppressing cells allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. The study is published April 29 in Nature.